Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today that it has been included in MDB Capital Group's "Best & Brightest" list of 150 innovative leaders for 2011.
MDB's Best & Brightest list is drawn from the universe of public companies with at least one U.S. patent and a market capitalization under $500 million. Companies included in the Best & Brightest list are ranked in the 90th percentile for technology leadership from more than 1,500 companies with U.S. patents granted.
Lou Scafuri, Chief Executive Officer of Syneron, commented, "Syneron's inclusion on MDB's Best & Brightest list is a testament to the strength of our innovative portfolio and pipeline of aesthetic devices and products for the professional and home-use markets. It also demonstrates our commitment to superior science and excellent clinical results, both of which create trust in our products. Looking forward, we will continue to have a strong focus on developing and acquiring best-in-class, category-creating technologies for aesthetic applications."
Syneron is celebrating 10 years of successful aesthetic treatments with its proprietary elos technology. elos is the first and only technology that simultaneously harnesses the power of both bi-polar radio frequency (RF) and optical energy (either laser or light). The Company also employs other proprietary technologies and patented systems for aesthetic procedures in the professional and home-use markets. Syneron recently unveiled new cutting-edge aesthetic products (http://www.easyir.com/easyir/prssrel.do?easyirid256C4E86057F2703&versionlive&prid716459) at the 69th Annual Meeting of the American Academy of Dermatology (AAD). The newly-launched products include ePrime Energy-Based Dermal Volumizer, CO2RE versatile Fractional CO2 Resurfacing System and elure Advanced Skin Lightening Technology. In addition, the Company featured the revolutionary eMatrix@ complete Sublative Rejuvenation@ system at the AAD.
About MDB Capital Group LLC
MDB Capital is an institutional research and investment banking firm that focuses exclusively on companies that possess market changing, disruptive intellectual property. For more information, visit www.mdb.com (http://www.mdb.com) .
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at www.syneron.com (http://www.syneron.com) .